Two-year results of an ongoing study show that intravitreal aflibercept injections in eyes with baseline moderate to severe nonproliferative diabetic retinopathy significantly decrease the chance to develop vision-threatening complications.
Those complications include proliferative diabetic retinopathy (PDR) and center-involved diabetic macular edema (CI-DME).
“However, through 2 years, preventive treatment with Eylea (Regeneron) did not confer visual acuity benefit compared with observation plus Eylea PRN if PDR or vision-reducing CI-DME developed,” Adam R. Glassman, MS, one of the